Interleukin- 28B: A prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response

APMIS

Volumn 123, Issue 9, 2015, Pages 765-771

  Resham, Saleha ^a   Manzoor, Sobia ^a   Imran, Muhammad ^a   Saalim, Muhammad ^a   Naseem, Sidrah ^a   Azam, Sikandar ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Chronic HCV; IL28B; Non responders; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; BIOLOGICAL MARKER; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PAKISTAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD; ADOLESCENT; CASE CONTROL STUDY; DRUG COMBINATION; GENETICS; GENOTYPE; HEPATITIS C, CHRONIC; METABOLISM; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; PAKISTAN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938829564     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12414     Document Type: Article

References (30)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:s21-9.
2. Dhingra A, Kapoor S, Alqahtani SA. Recent advances in the treatment of hepatitis C. Discov Med, 2014; 18:203-208.
3. Akbar H, Idrees M, Manzoor S, Rehman IU, Butt S, Yousaf M, et al. Hepatitis C virus infection: a review of the current and future aspects and concerns in Pakistan. J Gen Mol Virol 2009;1:12-8.
4. Imran M, Manzoor S, Azam S, Resham S. Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population. APMIS 2015;123:342-9.
5. Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007;89:729-34.
6. Saeed U, Waheed Y, Ashraf M. Hepatitis B and hepatitis C viruses: a review of viral genomes, viral induced host immune responses, genotypic distributions and worldwide epidemiology. Asian Pac J Trop Dis 2014;4:88-96.
7. Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002;97:1289-94.
8. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45, e7.
9. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001;75:6209-11.
10. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
11. Rembeck K. Impact of host genetic variants on natural history and treatment of hepatitis C virus infection. 2015.
12. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013;45:164-71.
13. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005;48:372-80.
14. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-82.
15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
16. Manns MP, Idrees M, Butt S, Awan Z, Sabar MF, ur Rehaman I, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet 2001;358:958-65.
17. Akbar H, Idrees M, Butt S, Awan Z, Sabar MF, ur Rehaman I, et al. High baseline interleukine-8 level is an Independent risk factor for the achievement of sustained virological response in chronic HCV patients. Infect Genet Evol 2011;11:1301-5.
18. Akhtar H, Akhtar S, Raheel U, Faheem M, Arshad M, Yameen M. Interferons as Immune Regulators: A Rivalry between HCV and Interferons. Journal of Clinical & Cellular Immunology 2013; doi: 10.4172/2155-9899.1000136.
19. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
20. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
21. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-7.
22. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1702-8.
23. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71.
24. Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50:369-77.
25. Bochud P-Y, Cai T, Overbeck K, Bochud M, Dufour J-F, Müllhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655-66.
26. Tanaka Y, Cai T, Overbeck K, Bochud M, Dufour J-F, Müllhaupt B, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
27. Katze MG. Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol 1995;3:75-8.
28. Gonzalez SA, Keeffe EB. IL-28B as a predictor of sustained virologic response in patients with chronic hepatitis C virus infection. Gastroenterol Hepatol 2011;7:366.
29. Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T, et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 2012;7:e37054.
30. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011;54:415-21.